Why this top-ranked IBD 50 stock just tumbled on its earnings
Exelixis stock toppled Thursday on a mixed second-quarter report, as sales of its bread-and-butter cancer drug lagged expectations.
Exelixis stock toppled Thursday on a mixed second-quarter report, as sales of its bread-and-butter cancer drug lagged expectations.